Artiva CMO sells shares to cover RSU taxes

Artiva Biotherapeutics' Chief Medical Officer, Subhashis Banerjee, sold 7,037 shares of common stock in an open-market transaction at a weighted average price of $9.0076 per share.

Rhea-AI Filing Summary

Artiva Biotherapeutics' Chief Medical Officer, Subhashis Banerjee, sold 7,037 shares of common stock in an open-market transaction at a weighted average price of $9.0076 per share. The company explains these automatic sales were made solely to cover tax withholding obligations tied to vested restricted stock units. Following the sale, Banerjee directly holds 144,963 shares.

Insider Trade Summary

Net Seller: 7,037 shares

Net Sell 1 txn

Insider Banerjee Subhashis

Role Chief Medical Officer

Sold 7,037 shs ($63K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,037	$9.0076	$63K

Holdings After Transaction: Common Stock — 144,963 shares (Direct)

Footnotes (2)

1. F1. The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.
2. F2. The weighted average sale price for the transaction reported was $9.0076, and the range of prices were between $8.7404 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Key Figures

Shares sold: 7,037 shares Weighted average sale price: $9.0076 per share Price range: $8.7404–$9.0104 per share +1 more

4 metrics

Shares sold 7,037 shares Open-market sale on 2026-05-19 to cover tax withholding

Weighted average sale price $9.0076 per share Automatic sell-to-cover transaction

Price range $8.7404–$9.0104 per share Range of prices for the reported sale

Shares held after transaction 144,963 shares Direct holdings of Subhashis Banerjee following the sale

Key Terms

sell-to-cover, restricted stock units, weighted average sale price, tax withholding obligations

4 terms

sell-to-cover financial

"The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations"

Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.

restricted stock units financial

"in connection with the vesting and release of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $9.0076"

tax withholding obligations financial

"to satisfy the tax withholding obligations of the Reporting Person"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Artiva Biotherapeutics (ARTV) disclose about Subhashis Banerjee's recent stock sale?

Artiva Biotherapeutics reported that Chief Medical Officer Subhashis Banerjee sold 7,037 shares of common stock. The company states the transaction was an automatic sell-to-cover trade to satisfy tax withholding obligations from vesting restricted stock units, not a discretionary open-market sale.

How many ARTV shares did the CMO sell and at what price?

Subhashis Banerjee sold 7,037 shares of Artiva common stock. The weighted average sale price was $9.0076 per share, with individual trade prices ranging between $8.7404 and $9.0104, according to the company’s disclosure for this Form 4 insider transaction.

Why were Subhashis Banerjee’s ARTV shares sold according to the Form 4 filing?

The filing explains that Artiva has a sell-to-cover policy for tax withholding. Banerjee’s 7,037 shares were automatically sold to satisfy tax obligations triggered by the vesting and release of restricted stock units, meaning the timing and size were driven by tax requirements.

How many Artiva Biotherapeutics shares does the CMO hold after this transaction?

After the reported sale, Chief Medical Officer Subhashis Banerjee directly holds 144,963 shares of Artiva common stock. This post-transaction balance reflects his remaining equity position following the automatic sale used to cover tax withholding obligations on vested restricted stock units.

Was the recent ARTV insider sale part of a discretionary trading decision?

The Form 4 indicates the sale was not discretionary. Artiva states the company’s sell-to-cover policy required selling 7,037 shares automatically to cover tax withholding generated by restricted stock unit vesting, rather than reflecting an independent trading decision by Subhashis Banerjee.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/19/2026 - 09:50 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Banerjee Subhashis

(Last) (First) (Middle)

C/O ARTIVA BIOTHERAPEUTICS, INC.

5505 MOREHOUSE DRIVE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		S		7,037(1)	D	$9.0076(2)	144,963	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Issuer has adopted a 'sell-to-cover' policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and release of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person.

2. The weighted average sale price for the transaction reported was $9.0076, and the range of prices were between $8.7404 and $9.0104. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Andrew Cronauer, Attorney-in-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)